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lence of comorbid conditions. There is substantial 1-year mean cost associated
with pediatric ADHD, even for stable responders on their pharmacotherapy. Nota-
bly, only one quarter of the cost of ADHD is due to medication.
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OBJECTIVES: To determine if IV droperidol or olanzapine, as adjuncts to midazo-
lam administration, improve sedation quality for the acutely agitated patient in the
Emergency Department (ED). METHODS: We undertook a randomised, double-
blind, placebo-controlled, double-dummy, clinical trial in three EDs (August 2009 to
March 2011). Adult patients requiring IV drug sedation for acute agitation were
enrolled. Each was randomized to receive an IV bolus of either saline (control),
droperidol (5mg) or olanzapine (5mg). This bolus was immediately followed by an
IV midazolam bolus (2.5-5mg) then additional boluses until sedation to a pre-de-
termined endpoint was achieved. The primary outcome was time to sedation.
Secondary outcomes were the need for ’rescue’ sedation and adverse events.
RESULTS: Three hundred and thirty-six patients were enrolled. The baseline char-
acteristics of the groups did not differ (p0.05). However, the median (IQR) times to
sedation (min) differed significantly (p0.001): control group 10 (4-25), droperidol 6
(3-10), olanzapine 5 (3-10). At any time point, patients in the droperidol and olan-
zapine groups were 1.6 times more likely to be sedated compared to controls:
droperidol and olanzapine group hazard ratios (95%CI) were 1.58 (1.21-2.06) and
1.64 (1.25-2.15), respectively, (p0.001). The droperidol and olanzapine groups re-
quired less rescue sedation and alternative drug use at any time after initial seda-
tion had been achieved (p0.05). The group adverse event profiles and lengths of
stay did not differ (p0.21 and 0.32, respectively). CONCLUSIONS: Droperidol or
olanzapine administration, as adjuncts to midazolam, is safe and significantly
improves sedation quality. These findings will inform best-practice for sedation of
the acutely agitated ED patient.
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OBJECTIVES: To summarize 1) mirror image studies of risperidone long-acting
injection (RIS-LAI) with respect to patient outcomes and 2) methodological weak-
nesses of this model. METHODS: Medline and Embase were searched for mirror
image studies that examined the same patients before and after switching to RIS-
LAI. We accepted clinical trials, database studies, or chart reviews. Clinical out-
comes included rates of hospitalization, duration of stay, and visits to emergency
room or outpatient clinics. Economic outcomes included cost of drugs, services, or
overall treatment. Results were analyzed descriptively. RESULTS: Twenty-three
studies were initially identified; 14 were rejected 7 were not RIS-LAI (i.e., oral RIS or
a mixture of drugs), 5 were duplicates or had overlapping results, and 2 were trials
comparing endpoint to baseline (not true mirror image studies). The 9 accepted
studies examined 2295 patients; 3 from UK (N385), 2 from USA (N1030), and 1
each from Germany (N119), New Zealand (N489), Sweden (N164), and Taiwan
(N108). Oral atypical antipsychotics were used as prior treatment in 53% of
patients, typical depots in 15%-45%, and multiple drugs in the remainder. These
papers reported 23 clinical outcomes (78% improved, 17% worse and 4% no change)
and 7 economic outcomes (71% decreased costs, 29% increased). Potential meth-
odological weaknesses include selection, measurement, and confounding biases.
The majority arise due inherent to lack of randomization. Most problematic is
channeling bias, where new drugs are selectively prescribed to failures and other
difficult cases. Selected studies had clear evidence of potential channeling bias
(severe disease, recent relapses). CONCLUSIONS: Switching to RIS-LAI was gener-
ally associated with improved patient clinical outcomes and lower costs. Channel-
ing bias needs to be avoided in mirror image analyses.
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OBJECTIVES: Although many treatments for ADHD are used off-label, in the UK,
only atomoxetine (ATX), dexamphetamine (DEX), and methylphenidate (MPH) are
licensed for use in children and adolescents. The objective of this review was to
systematically review and synthesise the existing clinical evidence, by indirectly
comparing the licensed treatments and a drug in development, lisdexamfetamine
(LDX). METHODS: A systematic review of randomised controlled clinical trials,
dated 1960 or later, in children and adolescents with ADHD that included at least
one of LDX, MPH, DEX, or ATX was performed. Network meta-analysis methods for
dichotomous outcomes were employed to evaluate treatment efficacy (response
defined by either the ADHD Rating Scale [ADHD-RS] or Clinical Global Impression–
Improvement scale [CGI-I]) and safety outcomes (all cause withdrawals [WDW] and
withdrawal due to adverse events [AEWDW]). RESULTS: The systematic review
included 32 trials, dated 2000 or later, including data on LDX, ATX, and MPH (ex-
tended release [MPH-ER], intermediate release [MPH-intR] and immediate release
[MPH-IR]). No trials for DEX meeting the inclusion criteria were found. Sufficient
data were identified for each of the outcomes: ADHD-RS, 16 trials; CGI-I, 20 trials;
WDW, 28 trials; and AEWDW, 27 trials. The efficacy relative risks (95% confidence
intervals [CI]) for LDX versus ATX were ADHD-RS, 1.41 (1.24, 1.61); CGI-I, 1.55 (1.28,
1.87); and for LDX versus MPH-ER (the most commonly used MPH formulation)
were ADHD-RS, 1.22 (1.08, 1.38); and CGI-I, 1.23 (1.04, 1.45). The safety relative risks
(95% confidence intervals [CI]) for LDX versus ATX were WDW, 0.75 (0.49, 1.17);
AEWDW, 1.72 (0.46, 6.37); and for LDX versus MPH-ER were WDW: 1.15 (0.74, 1.78),
and AEWDW: 2.70 (0.75, 9.71). CONCLUSIONS: The evidence synthesis of efficacy
favours LDX over ATX and MPH-ER for the treatment of ADHD. The analysis of
safety data proved inconclusive due to small event rates.
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OBJECTIVES: Clinical registration studies in Major Depressive Disorder (MDD) are
mostly controlled versus placebo. Regulators, clinicians, patients and payers there-
fore lack robust information to compare a new drug to the alternatives at time of
launch. Objective was to evaluate if relative antidepressant efficacy varies over
time. We evaluated the evolution of escitalopram and citalopram. METHODS: A
database of randomized-controlled trials (RCTs) of adults suffering from MDD was
built in order to provide a comprehensive assessment of antidepressant efficacy.
New-generation antidepressants launched from 1989 to 2002 and placebo were
included in this analysis. A 5-year period was chosen for the efficacy evaluation
(from 2002 to 2007). Analyses were performed on the Montgomery-Asberg Depres-
sion Scale (MADRS) adjusted mean change from baseline at 2 months (6-12 weeks)
using a Bayesian Mixed Treatment Comparison method with random effect and
Normal likelihood. Escitalopram efficacy evolution was presented as mean differ-
ence to placebo, ranking probabilities and mean rank. RESULTS: MADRS results
were reported at 2 months in 122 RCTs; 83 were selected for this analysis (excluding
treatments launched after 2002). Differences in MADRS total score versus placebo
increased from -3.39 [-5.06;-1.70] in 2002 to -3.76 [-4.63;-2.90] in 2007 for escitalo-
pram. Ranking probabilities curves for escitalopram and citalopram were mostly
overlapping in 2002, while a much clearer separation in favour of escitalopram
appeared in 2007. Mean ranks were respectively 6.8 and 6.2 in 2002; 4.4 and 7.3 in
2007 for escitalopram and citalopram. CONCLUSIONS: Escitalopram relative effi-
cacy increased from 2002 to 2007. This was mainly explained by new positive
superiority escitalopram studies. Time of launch did not appear always to be the
most appropriate to assess antidepressant efficacy mostly based on RCTs versus
placebo. Other outcomes and studies selection may have an impact on results.
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OBJECTIVES: Previous studies report varying frequency of switching and combina-
tion use of antidepressants between age groups and by socioeconomic character-
istics. The aim of this study was to analyse frequency of and predictors for combi-
nation use and switching of antidepressants in Swedish adults aged 20-34 years.
METHODS: The study population encompassed antidepressant users aged 20-34
years initiating use between January and June 2006 (n24,897). Data on filled anti-
depressants in 2006 were collected from the Swedish Prescribed Drug Register and
information on socioeconomic characteristics from Statistics Sweden. Clinical and
socioeconomic factors associated with use of at least two antidepressants and
switching were analyzed with multivariate logistic regression. RESULTS: In total,
17.1% purchased at least two antidepressant drugs. This was more common among
women, odds ratio (95% confidence interval): 1.16 (1.04 -1.28), among those who
started on mirtazapine compared to SSRIs: 2.33 (2.01-2.71), when a psychiatric care
facility issued the index prescription compared to primary care 1.19 (1.07-1.32),
among those born in Sweden with one parent born in Sweden 1.26 (1.09-1.45) and
those who had received social assistance 1.19 (1.03-1.37). It was less common when
an occupational health facility issued the index prescription 0.70 (0.53-0.94), with
declining length of follow up 0.73 (0.62-0.86), and with increasing length of educa-
tion. Among those who used at least two antidepressants, 71.6% were classified as
switchers. Switching was less common among those starting on mirtazapine: 0.69
(0.53-0.90), when the first prescription was issued in psychiatric care 0.74 (0.60-0.90)
and among individuals with at least two years of university education 0.60
(0.41-0.87). CONCLUSIONS:Almost one fifth used two or more antidepressants; the
majority was classified as switchers. Type of starting antidepressant, whether the
index prescription was issued by a psychiatric care facility and level of education
influenced use of at least two antidepressants and switching.
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OBJECTIVES: To investigate the cost of methylphenidate and atomoxetine pre-
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